Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × resiquimod × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Urinary Bladder Neoplasms 1 Sarcoma 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Esophageal Neoplasms 1 Chondrosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 38 Gemcitabine 26 Nivolumab 24 Paclitaxel 17 Cisplatin 14 Carboplatin 14 Cyclophosphamide 12 Capecitabine 11 Ipilimumab 10 Irinotecan 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 Docetaxel 8 Dexamethasone 8 Bevacizumab 8 Rituximab 7 spartalizumab 6 cemiplimab 6 Temozolomide 6 Sorafenib 6 Pemetrexed 6 Cetuximab 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5 fludarabine 5 Radiotherapy 5 Prednisone 5 ibrutinib 4 avelumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02126579 2024-02-28

MEL60

University of Virginia

Phase 1/2 Completed

50 enrolled 13 charts

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡